<?xml version="1.0" encoding="UTF-8"?>
<billStatus>
  <bill>
    <originChamber>House</originChamber>
    <recordedVotes />
    <congress>114</congress>
    <title>Adding Middle East Respiratory Syndrome to the FDA Priority Review Voucher Program Act</title>
    <latestAction>
      <text>Referred to the House Committee on Energy and Commerce.</text>
      <links />
      <actionDate>2016-09-14</actionDate>
    </latestAction>
    <notes />
    <updateDate>2018-11-21T21:23:45Z</updateDate>
    <amendments />
    <committees>
      <billCommittees>
        <item>
          <chamber>House</chamber>
          <type>Standing</type>
          <name>Energy and Commerce Committee</name>
          <activities>
            <item>
              <name>Referred to</name>
              <date>2016-09-14T14:02:50Z</date>
            </item>
          </activities>
          <systemCode>hsif00</systemCode>
          <subcommittees />
        </item>
      </billCommittees>
    </committees>
    <constitutionalAuthorityStatementText><![CDATA[<pre>[Congressional Record Volume 162, Number 139 (Wednesday, September 14, 2016)]From the Congressional Record Online through the Government Publishing Office [<a href='http://www.gpo.gov'>www.gpo.gov</a>]By Mr. PETERS:H.R. 6033.Congress has the power to enact this legislation pursuantto the following:Article I, Section 8[Page H5501]</pre>]]></constitutionalAuthorityStatementText>
    <relatedBills />
    <summaries>
      <billSummaries>
        <item>
          <updateDate>2016-09-14T04:00:00Z</updateDate>
          <actionDate>2016-09-14</actionDate>
          <text><![CDATA[<p><b>Adding Middle East Respiratory Syndrome to the FDA Priority Review Voucher Program Act</b></p> This bill amends the Federal Food, Drug, and Cosmetic Act to add Middle East respiratory syndrome to the list of tropical diseases under the priority review voucher program, which awards a voucher to the sponsor of a new drug or biological product that is approved to prevent or treat a tropical disease. (A voucher entitles the holder to have a future new drug or biological product application acted upon by the Food and Drug Administration within six months.)]]></text>
          <name>Introduced in House</name>
          <versionCode>00</versionCode>
          <lastSummaryUpdateDate>2016-09-29T11:38:37Z</lastSummaryUpdateDate>
          <actionDesc>Introduced in House</actionDesc>
        </item>
      </billSummaries>
    </summaries>
    <createDate>2016-09-15T05:09:08Z</createDate>
    <billNumber>6033</billNumber>
    <billType>HR</billType>
    <cosponsors>
      <item>
        <lastName>Rothfus</lastName>
        <firstName>Keith</firstName>
        <bioguideId>R000598</bioguideId>
        <district>12</district>
        <sponsorshipDate>2016-09-14</sponsorshipDate>
        <sponsorshipWithdrawnDate />
        <state>PA</state>
        <fullName>Rep. Rothfus, Keith J. [R-PA-12]</fullName>
        <isOriginalCosponsor>True</isOriginalCosponsor>
        <party>R</party>
        <identifiers>
          <bioguideId>R000598</bioguideId>
          <lisID>2158</lisID>
          <gpoId />
        </identifiers>
        <middleName>J.</middleName>
      </item>
      <item>
        <lastName>Boyle</lastName>
        <firstName>Brendan</firstName>
        <bioguideId>B001296</bioguideId>
        <district>13</district>
        <sponsorshipDate>2016-09-14</sponsorshipDate>
        <sponsorshipWithdrawnDate />
        <state>PA</state>
        <fullName>Rep. Boyle, Brendan F. [D-PA-13]</fullName>
        <isOriginalCosponsor>True</isOriginalCosponsor>
        <party>D</party>
        <identifiers>
          <gpoId />
          <lisID>2267</lisID>
          <bioguideId>B001296</bioguideId>
        </identifiers>
        <middleName>F.</middleName>
      </item>
    </cosponsors>
    <version>1.0.0</version>
    <actions>
      <item>
        <sourceSystem>
          <code>2</code>
          <name>House floor actions</name>
        </sourceSystem>
        <actionDate>2016-09-14</actionDate>
        <text>Referred to the House Committee on Energy and Commerce.</text>
        <committee>
          <name>Energy and Commerce Committee</name>
          <systemCode>hsif00</systemCode>
        </committee>
        <links />
        <type>IntroReferral</type>
        <actionCode>H11100</actionCode>
      </item>
      <item>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
        <actionDate>2016-09-14</actionDate>
        <text>Introduced in House</text>
        <committee />
        <links />
        <type>IntroReferral</type>
        <actionCode>Intro-H</actionCode>
      </item>
      <item>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
        <actionDate>2016-09-14</actionDate>
        <text>Introduced in House</text>
        <committee />
        <links />
        <type>IntroReferral</type>
        <actionCode>1000</actionCode>
      </item>
      <actionTypeCounts>
        <introducedInTheHouse>1</introducedInTheHouse>
        <introducedInHouse>1</introducedInHouse>
        <billReferrals>1</billReferrals>
      </actionTypeCounts>
      <actionByCounts>
        <houseOfRepresentatives>3</houseOfRepresentatives>
      </actionByCounts>
    </actions>
    <laws />
    <titles>
      <item>
        <titleType>Short Titles as Introduced</titleType>
        <title>Adding Middle East Respiratory Syndrome to the FDA Priority Review Voucher Program Act</title>
        <chamberName />
        <parentTitleType />
        <chamberCode />
      </item>
      <item>
        <titleType>Official Title as Introduced</titleType>
        <title>To expand the tropical disease product priority review voucher program to encourage treatments for the Middle East respiratory syndrome.</title>
        <chamberName />
        <parentTitleType />
        <chamberCode />
      </item>
      <item>
        <titleType>Display Title</titleType>
        <title>Adding Middle East Respiratory Syndrome to the FDA Priority Review Voucher Program Act</title>
        <chamberName />
        <parentTitleType />
        <chamberCode />
      </item>
    </titles>
    <cboCostEstimates />
    <sponsors>
      <item>
        <byRequestType />
        <lastName>Peters</lastName>
        <middleName>H.</middleName>
        <state>CA</state>
        <identifiers>
          <lisID>2113</lisID>
          <bioguideId>P000608</bioguideId>
          <gpoId />
        </identifiers>
        <bioguideId>P000608</bioguideId>
        <fullName>Rep. Peters, Scott H. [D-CA-52]</fullName>
        <firstName>Scott</firstName>
        <district>52</district>
        <party>D</party>
      </item>
    </sponsors>
    <committeeReports />
    <subjects>
      <billSubjects>
        <legislativeSubjects>
          <item>
            <name>Cardiovascular and respiratory health</name>
          </item>
          <item>
            <name>Drug safety, medical device, and laboratory regulation</name>
          </item>
          <item>
            <name>Drug therapy</name>
          </item>
          <item>
            <name>Infectious and parasitic diseases</name>
          </item>
        </legislativeSubjects>
        <policyArea>
          <name>Health</name>
        </policyArea>
      </billSubjects>
    </subjects>
    <introducedDate>2016-09-14</introducedDate>
    <calendarNumbers />
    <policyArea>
      <name>Health</name>
    </policyArea>
  </bill>
  <dublinCore xmlns:dc="http://purl.org/dc/elements/1.1/">
    <dc:format>text/xml</dc:format>
    <dc:language>EN</dc:language>
    <dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
    <dc:contributor>Congressional Research Service, Library of Congress</dc:contributor>
    <dc:description>This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.</dc:description>
  </dublinCore>
</billStatus>

